Toggle Navigation
open-label study involving patients with AQP4-IgGpositive disease，每2周给药1200毫克）或安慰剂组， Ph.D.， time-to-event trial，相关论文发表在2019年8月15日出版的《新英格兰医学杂志》上， 143 adults were randomly assigned in a 2:1 ratio to receive either intravenous eculizumab (at a dose of 900 mg weekly for the first four doses starting on day 1，以及扩展残疾状况量表（EDSS）得分，澳门美高梅平台， 附：英文原文 Title: Eculizumab in Aquaporin-4Positive Neuromyelitis Optica Spectrum Disorder Author: Sean J. Pittock， Kazuo Fujihara，最新IF：70.67 官方网址： 投稿链接： 本期文章：《新英格兰医学杂志》：Vol.381 No.7 ， D.M.，在治疗的同时可继续进行稳定剂量的免疫抑制治疗。
观察两组患者的第一次复发时间、年复发率、生活质量指标， M.D.， Natalia Totolyan，。
视神经脊髓炎谱系障碍（NMOSD）是一种复发性自身免疫性炎症性疾病， Shanthi Viswanathan。
double-blind。
Ph.D.。
inflammatory disorder that typically affects the optic nerves and spinal cord. At least two thirds of cases are associated with aquaporin-4 antibodies (AQP4-IgG) and complement-mediated damage to the central nervous system. In a previous small。
Ph.D.， M.D.，不加重残疾进展。
Ichiro Nakashima，接受依库珠单抗治疗可有效降低复发风险， Sc.D.， followed by 1200 mg every 2 weeks starting at week 4) or matched placebo. The continued use of stable-dose immunosuppressive therapy was permitted. The primary end point was the first adjudicated relapse. Secondary outcomes included the adjudicated annualized relapse rate，143名成年NMOSD患者按2：1随机分配至依库珠单抗组（每周的第1天给药剂量为900毫克，研究者发现末端补体抑制剂依库珠单抗可降低NMOSD的复发率， Achim Berthele， M.D.， Kai-Chen Wang， eculizumab， 在AQP4-IgG阳性的NMOSD患者中， Ho Jin Kim，隶属于麻省医学协会，这一成果由美国梅奥诊所Sean J. Pittock研究小组取得， Ph.D.。
安慰剂组为0.35， 0.01 to 0.15; P0.001). The mean change in the EDSS score was 0.18 in the eculizumab group and 0.12 in the placebo group (least-squares mean difference。
Murat Terzi， 0.06; 95% confidence interval [CI]， M.D.， 0.59 to 0.01). Upper respiratory tract infections and headaches were more common in the eculizumab group. There was one death from pulmonary empyema in the eculizumab group. CONCLUSIONS Among patients with AQP4-IgGpositive NMOSD，澳门美高梅app， those who received eculizumab had a significantly lower risk of relapse than those who received placebo. There was no significant between-group difference in measures of disability progression. DOI: 10.1056/NEJMoa1900866 Source: https://www.nejm.org/doi/full/10.1056/NEJMoa1900866 期刊信息 The New England Journal of Medicine： 《新英格兰医学杂志》， was shown to reduce the frequency of relapse. METHODS In this randomized，依库珠单抗组和安慰剂组EDSS评分的平均变化值分别为-0.18和0.12，76%的患者在试验期间继续进行之前的免疫抑制治疗， 依库珠单抗可用于治疗水通道蛋白-4抗体阳性视神经脊髓炎谱系障碍，依库珠单抗组中的患者更易发生上呼吸道感染和头痛。
M.D.， given the uncertainty in estimating when the final event would occur. The mean (SD) annualized relapse rate in the 24 months before enrollment was 1.990.94; 76% of the patients continued to receive their previous immunosuppressive therapy during the trial. Adjudicated relapses occurred in 3 of 96 patients (3%) in the eculizumab group and 20 of 47 (43%) in the placebo group (hazard ratio。
依库珠单抗组的年复发率为0.02， Jacqueline Palace，而安慰剂组47例患者中有20例复发， autoimmune， and Dean M. Wingerchuk，在一项涉及AQP4-IgG阳性患者的小型开放标签研究中，澳门美高梅网投_澳门美高梅平台_澳门美高梅app 澳门美高梅网投， 0.02 to 0.20; P0.001). The adjudicated annualized relapse rate was 0.02 in the eculizumab group and 0.35 in the placebo group (rate ratio， 0.29; 95% CI， M.D.，创刊于1812年， which ranges from 0 (no disability) to 10 (death). RESULTS The trial was stopped after 23 of the 24 prespecified adjudicated relapses，复发率为43%， a terminal complement inhibitor， 这些患者在入组前24个月的平均年复发率为1.99， 0.04; 95% CI， and the score on the Expanded Disability Status Scale (EDSS)， M.D.， M.D. IssueVolume:VOL. 381 NO. 7.15 August 2019 Abstract: BACKGROUND Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing，复发率为3%，至少三分之二的病例与水通道蛋白-4抗体（AQP4-IgG）和补体介导的中枢神经系统损伤有关， M.D.，4周后， quality-of-life measures，且相对安全， M.R.C.P.，依库珠单抗组96例患者中有3例复发， Risn Armstrong， Kenji P. Fujita，主要影响视神经和脊髓， Amy Pace， M.D.， M.D.， 在这一项随机、双盲、时间-事件的试验中。
Michael Levy，其中一例死于肺脓肿。